Govt. to give 12 Cr COVID vaccine doses in June 2021
7.94 crore doses were made available to the states in May 2021
7.94 crore doses were made available to the states in May 2021
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Subscribe To Our Newsletter & Stay Updated